Brief: Vaximm AG Reports Phase 2A Results For VXM01 And Avelumab Combo In Glioblastoma
26/03/2025 11:21
March 26 (Reuters) - OSR Holdings Inc OSRH.O: VAXIMM AG, AN OSR COMPANY, ANNOUNCES RESULTS FROM PHASE 2A TRIAL OF VXM01 AND AVELUMAB COMBINATION THERAPY IN GLIOBLASTOMA VAXIMM AG - PHASE 2A TRIAL SHOWS GOOD SAFETY AND TOLERABILITY PROFILE VAXIMM AG - NO SERIOUS ADVERSE EVENTS ATTRIBUTED TO VXM01 VAXIMM AG- DECREASED TUMOR SIZE OBSERVED IN RESPONDING PATIENTS Source text: ID:nPn8QQQdYa Further company coverage: OSRH.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on OSR Health
See all newsBrief: OSR Holdings Changes Corporate Name To OSR Health, Effective June 11, 2026
Brief: Osr Holdings Inc - In Preliminary Discussions For Acquisition Of 16% Controlling Stake In Sillajen - SEC Filing
Brief: Osr Holdings Inc - Vaximm AG Enters Binding Term Sheet With Bcm Europe AG - SEC Filing
Brief: Vaximm, An Osr Company, Receives Binding Term Sheet From Bcm Europe For Global Exclusive License Of Vxm01 With $30M Upfront And Up To $815M In Milestones
Brief: OSR Holdings Says Woori IO Shareholders Approve Share Exchange To Become Unit Of Co